Virtu Financial LLC Cuts Stake in IQVIA Holdings Inc. (NYSE:IQV)

Virtu Financial LLC trimmed its stake in IQVIA Holdings Inc. (NYSE:IQV) by 66.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,300 shares of the medical research company’s stock after selling 10,274 shares during the quarter. Virtu Financial LLC’s holdings in IQVIA were worth $1,256,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of IQV. Capital Performance Advisors LLP purchased a new stake in shares of IQVIA during the 3rd quarter valued at $27,000. Park Place Capital Corp purchased a new stake in IQVIA during the third quarter valued at about $28,000. Itau Unibanco Holding S.A. acquired a new stake in IQVIA during the second quarter worth about $29,000. International Assets Investment Management LLC purchased a new position in shares of IQVIA in the 2nd quarter worth about $32,000. Finally, Avior Wealth Management LLC lifted its stake in shares of IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on IQV shares. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Redburn Atlantic assumed coverage on shares of IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. Robert W. Baird reduced their target price on shares of IQVIA from $213.00 to $212.00 and set a “neutral” rating on the stock in a report on Wednesday. Barclays lowered their price target on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $257.60.

IQVIA Trading Down 0.3 %

IQV opened at $200.37 on Friday. The stock has a market capitalization of $36.37 billion, a PE ratio of 26.30, a P/E/G ratio of 2.07 and a beta of 1.49. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The firm’s fifty day moving average price is $213.40 and its 200 day moving average price is $224.61.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.